Organic Active Ingredients TRIZ Cases

New heterocyclic compounds treat carbapenem-resistant Acinetobacter baumannii infections by bypassing existing resistance mechanisms.

Formula I compounds inhibit wild-type and mutant NTRK kinases, resolving resistance issues in cancer treatment.

Segmented polymer structures prevent payload leakage by rupturing internal stresses upon target binding.

Triple-radius tablet geometry distributes stress to reduce damage from impacts and abrasion during production.

Targeted amino acid substitutions in AAV capsid proteins evade neutralizing antibodies, enabling repeat gene therapy administrations.

A pH-dependent pharmaceutical formulation modulates drug release rates across varying acidity levels to maintain therapeutic efficacy.

Formula I compounds inhibit hURAT1 transport to promote uric acid excretion, addressing toxicity and efficacy limits of existing gout treatments.

Small molecule inhibitors target specific bacterial toxins like BFT and ColA to reduce pathogenic effects in inflammatory bowel disease.

Peripherally restricted cannabinoid compounds target metabolic disorders without central nervous system penetration.

Fluorinated isochroman analogs enhance solubility and bioavailability while maintaining RXR agonist activity for treating glioblastoma and multiple sclerosis.

Periodic ulipristal acetate dosing improves ease of operation for infrequent sexual activity while maintaining contraceptive reliability.

Indazole derivatives inhibit ERK1 and ERK2 kinases to address unaddressed tumor growth in cancers like melanoma.

Engineered mRNA sequences incorporate multiple micro-RNA binding sites to enable differential protein expression across distinct cell types within target organs.

Naphthyridine azaquinolone stabilizes slipped DNA to halt somatic repeat expansions that drive neurodegenerative disease progression.

Novel substituted tetrahydroisoquinoline compounds inhibit factor XIa and plasma kallikrein, providing safer anticoagulation without monitoring requirements.

RNAi constructs degrade SCAP mRNA, lowering triglycerides and PCSK9 while preventing fibrosis progression in nonalcoholic fatty liver disease.

Hyper-compressed PLGA microparticles sustain drug release over weeks, eliminating frequent dosing and systemic toxicity.

Micellar structures mediate prasugrel dissolution at high pH, restoring bioavailability lost during proton pump inhibitor therapy.

KRAS G12C inhibitors featuring a piperazine core overcome EGFR therapy resistance by targeting mutant proteins in pancreatic, lung, and colorectal cancers.

Targeting DJ-1 protein levels reverses T cell senescence and improves vaccination efficacy in aging subjects.

Antiviral compounds with specific structural elements target hepatitis C virus genotypes while reducing toxicity and side effects.

C10-C30 carboxylic acid sterol esters treat psoriasis by regulating skin cells without the irritation, odor, or resistance associated with corticosteroids.

Transmucosal buprenorphine administration bypasses first-pass metabolism to minimize opioid adverse effects while managing chronic pain.

Beta-lactam derivatives inhibit glutaminyl-peptide cyclotransferase-like protein to treat diseases associated with aberrant activity.

An oil-based drug formulation ensures uniform coating of medical devices.

Cellular extracts from 3D cultures target tumor cells while sparing healthy tissue, reducing toxicity.

A sucralfate gel spray formulation stabilizes topical application through precise rheological control.

Intranasal rAAV vectors deliver enzymes across the blood-brain barrier, resolving limitations of peripheral therapies for neurological diseases.

L-arginine prebiotic composition restores commensal bacteria to modulate immune response against allergic reactions.

Chitosan-based tissue markers eliminate MRI interference and migration risks while maintaining imaging visibility.

19-nor C3,3-disubstituted steroids resolve inconsistent progesterone dose-response relationships by enhancing oral bioavailability and stability.

A liposome formulation encapsulates rapamycin using specific lipid ingredients to enhance bioavailability.

25HCDS cholesterol metabolite antagonizes LXR to reduce hepatic neutral lipids by 20-35% without triggering SREBP-1c upregulation.

Storing cysteamine formulations between 2 and 8 degrees Celsius reduces impurity formation and maintains chemical stability for up to 24 months.

A pharmaceutical kit delivers a corticosteroid-immunosuppressant blend for chronic dry eye alongside a high-concentration steroid for acute flare-ups.

A GGTase I inhibitor stabilizes the IP3R3 protein to sensitize cancer cells toward photodynamic therapy.

A zeolite and glucomannan composition reduces blood cholesterol through ionic exchange mechanisms.

Biocompatible nanoparticles enhance pharmaceutical compound efficiency through optimized pharmacokinetic profiles.

Selective AM2 receptor inhibitor compounds target cancer cell growth and metastasis in pancreatic cancer treatment.

Heterobifunctional compounds induce reversible CAR degradation, mitigating cytokine release syndrome while preserving anti-tumor efficacy.

Histone deacetylase inhibitors induce gamma globin expression via epigenetic modulation, reducing toxicity and myelosuppression compared to hydroxyurea.

A saline electrolyte solution mimics fasting chyme ionic composition and pH levels for enteral infusions.

Heteroaryl compounds inhibit necrotic cell death by targeting the RIP3-MLKL interaction pathway.

Surface functionalized iron oxide nanoparticles encapsulate cargo within cucurbituril[7] macrocycles for controlled release.

Segmented pyrimidine synthesis manages development complexity while reducing plasma triglycerides via MOGAT-2 inhibition.

Alkyl sulfate salts prevent aminopyrazole gelation during milling, enabling rapid dissolution without formulation binding.